# US 2010/0166874 A1 · Technology for Preparation of Macromolecular Microspheres

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166874 A1
- Document ID: US20100166874A1
- Status: Published application
- Kind: A1
- Application number: 12/633,773
- Filed: 2009-12-08
- Published: 2010-07-01
- Earliest claimed: 2006-01-24
- Inventors: Michael P. Malakhov; Fang Fang
- Web page: https://patentgrep.com/patent/US20100166874A1

## CPC

- A61K 9/1682: {Processes}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 23/00: Anaesthetics
- A61P 25/16: Anti-Parkinson drugs
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/16: for influenza or rhinoviruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of making protein-based microparticles, comprising:
a) mixing together: (i) a solution containing a protein in an aqueous solvent, (ii) a counterion and (iii) one or more organic solvents, wherein each organic solvent in the resulting mixture is volatile and none are a polymer; and
b) providing the resulting mixture at or cooling the resulting mixture to a temperature below about 25° C., whereby microparticles comprising the protein are formed.

### Claim 3 (depends on 2)

The method of claim 2, wherein the organic solvent is selected from among methanol, ethanol, 1-propanol, isopropanol, tert-butyl alcohol, butanol, acetone, acetonitrile, acetic acid, ethyl acetate, methyl ethyl ketone, methyl t-butyl ether, and dimethyl sulfoxide.

### Claim 4 (depends on 2)

The method of claim 2, wherein the counterion is an anionic compound.

### Claim 5 (depends on 4)

The method of claim 4, wherein the counterion is selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof.

### Claim 6 (depends on 2)

The method of claim 2, wherein the protein is a sialidase fusion protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sequence of the sialidase fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:17.

### Claim 8 (depends on 2)

The method of claim 2, wherein the temperature is between about 4° C. to about −45° C.

### Claim 9 (depends on 2)

The method of claim 2, further comprising adding an active agent to step a) or to a suspension of the formed microspheres, wherein the active agent is selected from among antidiabetics, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diuretics, electrolytes, enzymes, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, antineoplastics, glycoproteins, nucleoproteins, lipoproteins, ophthalmics, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, vaccines, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides, polysaccharides and nutritional supplements; whereby the microspheres comprise the active agent.

### Claim 10 (depends on 2)

The method of claim 2, wherein the organic solvent is present in the mixture at from about 0.1% to about 50% v/v.

### Claim 11 (depends on 10)

The method of claim 10, wherein the organic solvent is present in the mixture at about 1% to about 30% v/v.

### Claim 12 (depends on 2)

The method of claim 2, wherein the size of the microparticles is from about 0.5 μm to about 5.0 μm.

### Claim 13

A method of making protein-based microparticles, comprising:
a) providing a solution comprising a protein, a counterion, an aqueous solvent and one or more organic solvents, wherein each organic solvent present in the solution is a volatile solvent other than ethanol and none are a polymer; and
b) providing the solution at or cooling the solution to a temperature below about 25° C., whereby microparticles comprising the protein are formed.

### Claim 14 (depends on 13)

The method of claim 13, wherein the organic solvent is selected from among methanol, 1-propanol, isopropanol, tert-butyl alcohol, butanol, acetone, acetonitrile, acetic acid, ethyl acetate, methyl ethyl ketone, methyl t-butyl ether, and dimethyl sulfoxide.

### Claim 15 (depends on 13)

The method of claim 13, wherein the counterion is an anionic compound.

### Claim 16 (depends on 15)

The method of claim 15, wherein the counterion is selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof.

### Claim 17 (depends on 13)

The method of claim 13, wherein the protein is a sialidase fusion protein.

### Claim 18 (depends on 17)

The method of claim 17, wherein the sequence of the sialidase fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:17.

### Claim 19 (depends on 13)

The method of claim 13, wherein the temperature is between about 4° C. to about −45° C.

### Claim 20 (depends on 13)

The method of claim 13, further comprising adding an active agent to step a) or to a suspension of the formed microspheres, wherein the active agent is selected from among antidiabetics, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diuretics, electrolytes, enzymes, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, antineoplastics, glycoproteins, nucleoproteins, lipoproteins, ophthalmics, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, vaccines, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides, polysaccharides and nutritional supplements; whereby the microspheres comprise the active agent.

### Claim 21 (depends on 13)

The method of claim 13, wherein the amount of organic solvent added is from about 0.1% to about 50% v/v.

### Claim 22 (depends on 21)

The method of claim 21, wherein the organic solvent is present in the mixture at about 1% to about 30% v/v.

### Claim 23 (depends on 13)

The method of claim 13, wherein the size of the microparticles is from about 0.5 μm to about 5.0 μm.

### Claim 24

A method of making protein-based microparticles, comprising:
a) providing a solution comprising a protein, a counterion, an aqueous solvent and an organic solvent;
b) providing the solution at or cooling the solution to a temperature below about 25° C., whereby a composition containing microparticles comprising the protein is formed; and
c) without any other separation and/or washing steps, isolating the microparticles from unincorporated aqueous solvent and organic solvent by lyophilization.

### Claim 25 (depends on 24)

The method of claim 24, wherein the organic solvent is selected from among methanol, ethanol, 1-propanol, isopropanol, tert-butyl alcohol, butanol, acetone, acetonitrile, acetic acid, ethyl acetate, methyl ethyl ketone, methyl t-butyl ether, and dimethyl sulfoxide.

### Claim 26 (depends on 24)

The method of claim 24, wherein the counterion is an anionic compound.

### Claim 27 (depends on 26)

The method of claim 26, wherein the counterion is selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof.

### Claim 28 (depends on 24)

The method of claim 24, wherein the protein is a sialidase fusion protein.

### Claim 29 (depends on 28)

The method of claim 28, wherein the sequence of the sialidase fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:17.

### Claim 30 (depends on 24)

The method of claim 24, wherein the temperature is between about 4° C. to about −45° C.

### Claim 31 (depends on 24)

The method of claim 24, further comprising adding an active agent to step a) or to a suspension of the formed microspheres, wherein the active agent is selected from among antidiabetics, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diuretics, electrolytes, enzymes, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, antineoplastics, glycoproteins, nucleoproteins, lipoproteins, ophthalmics, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, vaccines, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides, polysaccharides and nutritional supplements; whereby the microspheres comprise the active agent.

### Claim 32 (depends on 24)

The method of claim 24, wherein the organic solvent is present in the mixture at about 0.1% to about 50% v/v.

### Claim 33 (depends on 32)

The method of claim 32, wherein the organic solvent is present in the mixture at about 1% to about 30% v/v.

### Claim 34 (depends on 24)

The method of claim 24, wherein the size of the microparticles is from about 0.5 μm to about 5.0 μm.

### Claim 35

A method of making a protein-based composition, comprising:
a) providing a solution comprising a protein, a counterion, an aqueous solvent and an organic solvent;
b) providing the solution at or cooling the solution to a temperature below about 25° C., whereby a composition containing microparticles comprising the protein is formed; and
c) without any other separation and/or washing steps, isolating the microparticles from the unincorporated reagents by lyophilization.

### Claim 36

A method of making protein-based microparticles, comprising:
a) providing a solution comprising a protein, a counterion, an aqueous solvent and an organic solvent, wherein the organic solvent is selected from among methanol, ethanol, 1-propanol, isopropanol, tert-butyl alcohol, butanol, acetone, acetonitrile, acetic acid, ethyl acetate, methyl ethyl ketone, methyl t-butyl ether, and dimethyl sulfoxide, and the counterion is selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof; and
b) providing the solution at or cooling the solution to a temperature below about 25° C., whereby microparticles comprising the protein are formed.

### Claim 37 (depends on 36)

The method of claim 36, wherein the protein is a sialidase fusion protein.

### Claim 38 (depends on 37)

The method of claim 37, wherein the sequence of the sialidase fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:17.

### Claim 39 (depends on 36)

The method of claim 36, wherein the temperature is between about 4° C. to about −45° C.

### Claim 40 (depends on 36)

The method of claim 36, further comprising adding an active agent to step a) or to a suspension of the formed microspheres, wherein the active agent is selected from among antidiabetics, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diuretics, electrolytes, enzymes, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, antineoplastics, glycoproteins, nucleoproteins, lipoproteins, ophthalmics, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, vaccines, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides, polysaccharides and nutritional supplements; whereby the microspheres comprise the active agent.

### Claim 41 (depends on 36)

The method of claim 36, wherein the organic solvent is present in the mixture at about 0.1% to about 50% v/v.

### Claim 42 (depends on 41)

The method of claim 41, wherein the organic solvent is present in the mixture at about 1% to about 30% v/v.

### Claim 43 (depends on 42)

The method of claim 42, wherein the size of the microparticles is from about 0.5 μm to about 5.0 μm.

### Claim 44

A method of making protein-based microparticles, comprising:
a) providing a solution comprising a protein, a counterion, an aqueous solvent and one or more organic solvents, wherein the total amount of organic solvent(s) in the resulting solution is 50% or less v/v and each organic solvent present in the solution is volatile and none are a polymer; and
b) providing the solution at or cooling the solution to a temperature below about 25° C., whereby microparticles comprising the protein are formed.

### Claim 45 (depends on 44)

The method of claim 44, wherein the organic solvent is selected from among methanol, ethanol, 1-propanol, isopropanol, tert-butyl alcohol, butanol, acetone, acetonitrile, acetic acid, ethyl acetate, methyl ethyl ketone, methyl t-butyl ether, and dimethyl sulfoxide.

### Claim 46 (depends on 44)

The method of claim 44, wherein the counterion is an anionic compound.

### Claim 47 (depends on 46)

The method of claim 46, wherein the counterion is selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof.

### Claim 48 (depends on 44)

The method of claim 44, wherein the protein is a sialidase fusion protein.

### Claim 49 (depends on 48)

The method of claim 48, wherein the sequence of the sialidase fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:17.

### Claim 50 (depends on 44)

The method of claim 44, wherein the temperature is between about 4° C. to about −45° C.

### Claim 51 (depends on 44)

The method of claim 44, further comprising adding an active agent to step a) or to a suspension of the formed microspheres, wherein the active agent is selected from among antidiabetics, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diuretics, electrolytes, enzymes, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, antineoplastics, glycoproteins, nucleoproteins, lipoproteins, ophthalmics, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, vaccines, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides, polysaccharides and nutritional supplements; whereby the microspheres comprise the active agent.

### Claim 52 (depends on 44)

The method of claim 44, wherein the organic solvent is present in the mixture at about 0.1% to about 50% v/v.

### Claim 53 (depends on 52)

The method of claim 52, wherein the organic solvent is present in the mixture at about 1% to about 30% v/v.

### Claim 54 (depends on 44)

The method of claim 44, wherein the concentration of counterion added is from about 0.1 mM to about 100 mM.

### Claim 55 (depends on 44)

The method of claim 44, wherein the concentration of counterion added is from about 0.1 mM to about 40 mM.

### Claim 56 (depends on 44)

The method of claim 44, wherein the concentration of counterion added is from about 0.1 mM to about 15 mM.

### Claim 57 (depends on 54)

The method of claim 54, wherein the concentration of counterion added is from about 0.2 mM to about 50 mM.

### Claim 58 (depends on 57)

The method of claim 57, wherein the concentration of counterion added is from about 0.5 mM to about 20 mM.

### Claim 59 (depends on 44)

The method of claim 44, wherein the size of the resulting microparticles is from about 0.001 μm to about 50 μm.

### Claim 60 (depends on 44)

The method of claim 44, wherein the size of the resulting microparticles is from about 0.3 μm to about 30 μm.

### Claim 61 (depends on 44)

The method of claim 44, wherein the size of the resulting microparticles is from about 0.5 μm to about 10 μm.

### Claim 62 (depends on 44)

The method of claim 44, wherein the size of the resulting microparticles is from about 0.5 μm to about 6.5 μm.

### Claim 63 (depends on 44)

A composition, comprising microparticles formed according to the method of claim 44.

### Claim 64 (depends on 63)

The composition of claim 63, wherein the microparticles comprise a counterion selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof.

### Claim 65 (depends on 64)

The composition of claim 64, wherein the amount of counterion in the microparticles is from about 0.5% w/w to about 5% w/w.

### Claim 66 (depends on 64)

The composition of claim 64, wherein the protein is a sialidase fusion protein comprising a sialidase catalytic domain and a glycosaminoglycan (GAG)-binding domain, wherein the catalytic domain of the sialidase is the only portion of the sialidase in the sialidase fusion protein.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the sialidase is Actinomyces viscosus sialidase.

### Claim 68 (depends on 66)

The composition of claim 66, wherein the GAG-binding domain is selected from among the GAG-binding domain of human platelet factor 4 (SEQ ID NO:3), the GAG-binding domain of human interleukin 8 (SEQ ID NO:4), the GAG-binding domain of human antithrombin 111 (SEQ ID NO:5), the GAG-binding domain of human apoprotein E (SEQ ID NO:6), the GAG-binding domain of human angio-associated migratory protein (SEQ ID NO:7) and the GAG-binding domain of human amphiregulin (SEQ ID NO:8).

### Claim 69 (depends on 68)

The composition of claim 68, wherein the GAG-binding domain is that of human amphiregulin (SEQ ID NO:8).

### Claim 70 (depends on 69)

The composition of claim 69, wherein the amino acid sequence of the sialidase fusion protein comprises the sequence of amino acid residues set forth in SEQ ID NO:17.

### Claim 71 (depends on 63)

The composition of claim 63, wherein the size of the microparticles is from about 0.001 μm to about 50 μm.

### Claim 72 (depends on 71)

The composition of claim 71, wherein the size of the resulting microparticles is from about 0.3 μm to about 30 μm.

### Claim 73 (depends on 72)

The composition of claim 72, wherein the size of the resulting microparticles is from about 0.5 μm to about 10 μm.

### Claim 74

A composition comprising microparticles of a protein and a counterion, wherein:
(a) the size of the microparticles is from about 0.5 μm to about 10 μm; and
(b) the counterion is selected from among citrate, phosphate, sulfate, pivalate, rubidium, bromine, perchlorate, triethylamine, glycine, itaconate, and arginine, and any salt, acid, or base form thereof.

### Claim 75 (depends on 74)

The composition of claim 74, wherein the protein is a sialidase fusion protein comprising a sialidase catalytic domain and a glycosaminoglycan (GAG)-binding domain, wherein the catalytic domain of the sialidase is the only portion of the sialidase in the sialidase fusion protein.
